IDH1 and acute myeloid leukemia: In a phase IB trial, newly diagnosed IDH1-mutant AML patients treated with ivosidenib and AZA showed deep and durable treatment responses (overall response rate (ORR) 78.3%; complete remission (CR) 60.9%; and 12-month survival estimate 82%) [114].